Certara, Inc. is a provider of biosimulation software and technology-enabled services for the biopharmaceutical industry. Headquartered in Radnor, Pennsylvania, the company helps drug developers and regulatory agencies simulate drug behavior, optimize clinical trials, and streamline regulatory submissions. Its solutions are designed to accelerate the drug discovery and development process while reducing the need for human and animal testing.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
418,838
385,148
354,337
335,644
Cost of Sales
161,126
154,516
141,022
132,577
Gross Profit
257,712
230,632
213,315
203,067
Selling, General & Administrative Expenses
139,100
141,665
127,407
99,181
Depreciation & Amortization Expenses
56,556
53,593
45,525
43,160
Research & Development Expenses
41,040
37,105
34,173
28,205
Other Operating Expenses
—
—
46,984
—
Operating Profit
21,016
(1,731)
(40,774)
32,521
Interest Expense
(19,738)
(21,520)
(22,916)
(17,773)
Non-Operating Income
6,338
6,067
8,547
4,007
Total Non-Operating Income
(13,400)
(15,453)
(14,369)
(13,766)
Income Before Provision for Income Taxes
7,616
(17,184)
(55,143)
18,755
Provision for Income Taxes
9,211
(5,133)
214
4,024
Consolidated Net Income
(1,595)
(12,051)
(55,357)
14,731
Net Income Attributable to Common Shareholders
(1,595)
(12,051)
(55,357)
14,731
Basic EPS
-0.01
-0.08
-0.35
0.09
Diluted EPS
-0.01
-0.08
-0.35
0.09
Basic Weighted Average Shares Outstanding
160,394
160,393
158,936
156,877
Diluted Weighted Average Shares Outstanding
160,394
160,393
158,936
159,354
Shares Outstanding
159,140
161,009
159,848
159,526
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
189,392
179,183
234,951
236,586
Total Cash and Cash Equivalents
189,392
179,183
234,951
236,586
Accounts Receivable
103,525
102,189
84,857
82,584
Total Trade Receivables
103,525
102,189
84,857
82,584
Other Current Assets
22,202
29,480
20,393
23,082
Total Current Assets
315,119
310,852
340,201
342,252
Net Property, Plant & Equipment
13,792
16,008
12,274
16,827
Net Intangible Assets
447,476
485,214
487,043
486,782
Goodwill
773,311
757,038
716,333
717,743
Other Long-Term Assets
6,884
5,992
7,289
9,318
Total Assets
1,556,582
1,575,104
1,563,140
1,572,922
Accounts Payable
3,426
3,502
5,171
7,533
Accrued Expenses
67,131
56,451
56,779
35,403
Current Portion of Long-Term Debt
2,963
3,000
3,020
3,020
Unearned Revenue
75,412
77,829
60,678
52,209
Other Current Liabilities
4,453
5,306
4,375
4,993
Total Current Liabilities
153,385
146,088
130,023
103,158
Long-Term Debt
290,131
292,425
288,217
289,988
Leases
8,438
11,166
6,955
10,133
Other Long-Term Liabilities
41,833
66,769
91,105
89,982
Total Long-Term Liabilities
340,402
370,360
386,277
390,103
Total Liabilities
493,787
516,448
516,300
493,261
Common Stock
1,641
1,620
1,603
1,596
Treasury Stock
(66,663)
(18,184)
(9,401)
(3,000)
Additional Paid-in Capital
1,255,653
1,216,925
1,178,461
1,150,168
Accumulated Other Comprehensive Income
2,040
(13,424)
(7,593)
(8,230)
Retained Earnings
(129,876)
(128,281)
(116,230)
(60,873)
Total Common Shareholders' Equity
1,062,795
1,058,656
1,046,840
1,079,661
Total Shareholders' Equity
1,062,795
1,058,656
1,046,840
1,079,661
Total Liabilities and Shareholders' Equity
1,556,582
1,575,104
1,563,140
1,572,922
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(1,595)
(12,051)
(55,357)
14,731
Depreciation & Amortization
75,162
68,033
56,071
52,470
Share-Based Compensation Expense
33,079
34,774
28,300
30,345
Other Adjustments
(10,206)
(2,107)
56,790
(8,899)
Changes in Trade Receivables
428
(16,225)
152
(15,009)
Changes in Unearned Revenue
(3,018)
13,834
28
9,530
Changes in Other Operating Activities
2,475
(5,792)
(3,229)
9,375
Cash from Operating Activities
96,325
80,466
82,755
92,543
Capital Expenditure
(1,760)
(1,625)
(1,777)
(1,430)
Purchases of Intangible Assets
(24,796)
(19,416)
(13,545)
(11,099)
Payments for Business Acquisitions
—
(91,327)
(64,228)
(15,308)
Cash from Investing Activities
(26,556)
(112,368)
(79,550)
(27,837)
Issuance of Long-Term Debt
—
6,305
—
—
Repayments of Long-Term Debt
(2,991)
(2,255)
(3,045)
(3,313)
Net Issuance / (Repayments) of Long-Term Debt
(2,991)
4,050
(3,045)
(3,313)
Repurchases of Common Shares
(42,610)
—
—
—
Net Issuance / (Repurchases) of Common Shares
(42,610)
—
—
—
Other Financing Activities
(18,385)
(25,060)
(11,557)
(4,050)
Cash from Financing Activities
(63,986)
(21,010)
(9,447)
(7,363)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
—
—
—
(4,279)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash